乳腺癌患者中断abemaciclib的预测因素:一个多中心的回顾性队列研究
Noriaki Kataoka1, Takeo Hata2,3, Kouichi Hosomi4
1Department of Pharmacy, Osaka Medical and Pharmaceutical University Hospital, 2-7, Daigaku-Machi, Takatsuki, Osaka, 569-8686, Japan. noriaki.kataoka@ompu.ac.jp.
乳腺癌患者较低的体重预示着由于不良事件而中止abemaciclib. 密切监测和频繁访问对于这些患者开始循环林依赖性激酶4和6抑制剂治疗至关重要.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿贝马西克利布是一种依赖于环林的激酶4和6抑制剂,用于乳腺癌治疗.
- 暂停使用abemaciclib的预测因素尚未完全理解,这会影响治疗的疗效.
研究的目的:
- 为了确定乳腺癌患者中断abemaciclib的预测因素.
- 分析导致由于不良事件而导致暂时暂停或减少abemaciclib剂量的因素.
主要方法:
- 一项回顾性研究包括147名接受abemaciclib.lib治疗的乳腺癌患者.
- 多变量考克斯回归分析被用来确定停止,暂停或减少剂量的预测因素.
主要成果:
- 较低的基线体重 (<54公斤),骨转移和低血红蛋白 (≤12.4g/dL) 预测了阿贝马西利布的整体中止.
- 肝酶升高和胃肠道症状是停止治疗的主要原因.
- 低基线体重也预测了暂时暂停或减少剂量,主要是由于中性质衰竭和腹.
结论:
- 体重较低 (<54公斤) 的患者面临着与abemaciclib相关的不良事件和治疗中止的更高风险.
- 建议在开始治疗abemaciclib的低体重患者中对不良事件进行主动监测,并增加医疗访问频率.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
相关概念视频
Cancer Survival Analysis
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Inhibition of Cdk Activity
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Assumptions of Survival Analysis
